TICKERNERD
Menu
ACBACBHealthcare · Drug Manufacturers - Specialty & Generic

ACB Stock Forecast: Aurora Cannabis, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.94
+3.41% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$249.4M
Ticker Nerd rank
34 / 100
Median analyst target
—
Analysts covering
5
Total return, dividends reinvested
1W
+7.1%
1M
+47.0%
YTD
−6.6%
1Y
−17.6%
From 52W high
−36.8%
From 52W low
+52.7%
$2.58
$6.23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aurora Cannabis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
76
Issuance
71
Size
65
Revisions
51
Quality
44
Value
31
Volatility
24
Growth
17
Momentum
17

Accruals (76): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (17): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26ACB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
2 Buy3 Hold0 Sell
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
27 June 2024Zuanic & AssociatesInitiatesNeutral—
16 June 2023CIBCMaintainsNeutral$1.75 → $1.00
15 June 2023Canaccord GenuityMaintainsHold$1.50 → $0.80
13 Feb 2023CIBCMaintainsNeutral$2.25 → $1.75
21 Sept 2022Piper SandlerMaintainsNeutral$4.00 → $3.00
28 Sept 2021MKM PartnersUpgradeNeutral—
18 Dec 2020BMO CapitalDowngradeUnderperform$9.00
25 Nov 2020B of A SecuritiesDowngradeNeutral—
25 Nov 2020Bank of AmericaDowngradeNeutral—
25 Nov 2020Cowen & Co.InitiatesOutperform—
25 Nov 2020DesjardinsInitiatesBuy—
25 Nov 2020JefferiesInitiatesBuy—
25 Nov 2020Ladenburg ThalmannDowngradeNeutral—
25 Nov 2020MKM PartnersInitiatesSell—
25 Nov 2020NeedhamInitiatesHold—
25 Nov 2020Piper JaffrayMaintainsNeutral—
25 Nov 2020Piper SandlerMaintainsNeutral—
25 Nov 2020Seaport GlobalInitiatesNeutral—
25 Nov 2020StifelDowngradeSell—
25 Nov 2020Stifel NicolausInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ACB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Aurora Cannabis, Inc. (ACB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.8×

Cheaper than 37% of US stocks

Price / sales
0.8×

Cheaper than 75% of US stocks

Price / book
0.7×

Cheaper than 82% of US stocks

EV / EBITDA
−6.0×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
−8.8%

Higher than 16% of US stocks

Earnings growth (YoY)
−31.1%

Higher than 15% of US stocks

Gross margin
52.7%

Higher than 66% of US stocks

Operating margin
−12.9%

Higher than 23% of US stocks

Net margin
−38.3%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−9.4%

Higher than 36% of US stocks

Return on assets
−3.7%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ACBAurora Cannabis, Inc.$249.4M
34
EBSEmergent BioSolutions, Inc.$263.0M
90
AKBAAkebia Therapeutics, Inc.$242.9M
75
ORGOOrganogenesis Holdings, Inc.$228.4M
52
ANIKAnika Therapeutics, Inc.$291.9M
100
SIGASIGA Technologies, Inc.$217.8M
42
CRDLCardiol Therapeutics, Inc.$217.4M
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aurora Cannabis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACB news & analysis

The Cannabis M&A Wave Is Here. Curaleaf Proved It.

The Motley Fool · 23 Aug 2026neutral

The article reports that a wave of mergers and acquisitions is emerging in the U.S. cannabis industry, citing Curaleaf as evidence. It notes that Green Thumb Industries has been among the few consistently profitable U.S. cannabis companies, with revenue and earnings growth in the second quarter.

Why it matters — An Aurora Cannabis watcher would care because the reported consolidation trend could reshape the broader competitive landscape of the cannabis sector in which ACB operates.

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

The Motley Fool · 21 Aug 2026neutral

Curaleaf has made an unsolicited, hostile takeover bid for Aurora Cannabis. Aurora recently completed its acquisition of Safari Flower.

Why it matters — An ACB watcher would care because a hostile takeover bid directly affects Aurora's ownership and future direction, while its recent Safari Flower acquisition adds context to its current position.

Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?

The Motley Fool · 20 Aug 2026neutral

Curaleaf has reiterated the takeover offer it made public last week for Aurora Cannabis. Aurora stock continues to trade at a discount to the base offer price.

Why it matters — The reiteration confirms that an attempted hostile takeover of Aurora is actively under way, a development ACB watchers will monitor for its effect on the company's valuation.

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD

24/7 Wall Street · 19 Aug 2026neutral

Shares of Tilray Brands rose 6% to $4.75 on Wednesday afternoon, while Canopy Growth climbed 3% and Aurora Cannabis gained 4%, part of a broad bid for beaten-down speculative stocks. The report notes Tilray remains down 47% year-to-date.

Why it matters — Aurora Cannabis watchers would note that the stock participated in a sector-wide rally among cannabis and speculative names, with the move reflecting broader market sentiment rather than company-specific news.

Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market

PRNewsWire · 19 Aug 2026positive

Aurora Cannabis announced it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy, expanding its distribution access to the UK medical cannabis market. The company described the acquisitions as a further strategic milestone in growing its international medical cannabis business.

Why it matters — ACB watchers would care because the acquisitions broaden Aurora's distribution reach in the UK medical cannabis market, supporting the company's stated expansion in international medical cannabis.

FAQ

Frequently asked questions about ACB stock

Is ACB stock a buy right now?

Of the 5 analysts covering Aurora Cannabis, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurora Cannabis, Inc. 34 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACB?

As at 22 Aug 2026, Aurora Cannabis, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (76 of 100).

What is the ACB stock forecast for 2030?

No analyst covering Aurora Cannabis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACB are extrapolating price history, which says nothing about the business.

How has ACB stock performed over the past year?

Aurora Cannabis, Inc. returned -17.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aurora Cannabis, Inc. do?

Aurora Cannabis Inc. is a Canadian cannabis producer specializing in the cultivation, processing, and sale of medical and adult-use cannabis products.

What is the latest news on ACB?

The most recent item we track (The Motley Fool, 23 Aug 2026): "The Cannabis M&A Wave Is Here. Curaleaf Proved It.". The article reports that a wave of mergers and acquisitions is emerging in the U.S. cannabis industry, citing Curaleaf as evidence. It notes that Green Thumb Industries has been among the few consistently profitable U.S. cannabis companies, with revenue and earnings growth in the second quarter.

Company

About Aurora Cannabis, Inc.

Aurora Cannabis Inc. is a Canadian cannabis producer specializing in the cultivation, processing, and sale of medical and adult-use cannabis products. Headquartered in Edmonton, Alberta, the company operates through two main segments: Cannabis and Plant Propagation, providing both finished cannabis goods and starter materials for commercial growers. Aurora Cannabis offers dried flower, pre-rolls, oils, vapes, edibles, and derivative products, addressing a range of consumer and patient needs in regulated markets. It markets its products under multiple brands and participates in both domestic and international medical cannabis channels, supported by export agreements and partnerships. In addition, its plant propagation business supplies agricultural and horticultural sectors with high-quality starter plants. Positioned within the healthcare and specialty drug manufacturing industry, Aurora Cannabis plays a notable role in the evolving legal cannabis market, linking pharmaceutical-style production standards with consumer and medical demand across Canada and select global regions.

CEO Mr. Miguel Martin · 1,028 employees · Canada · https://www.auroramj.com